The ICE Aspiration System features a dual-lumen design to create the patented Surge Aspiration technology. Credit: Expanse Medical/PR Newswire.

The US Food and Drug Administration (FDA) has issued 510(k) clearance to Expanse ICE’s aspiration thrombectomy system ICE Aspiration System.

The FDA clearance marks a significant milestone in the medical device sector, particularly in the field of thrombectomy treatments, stated the company.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

The ICE Aspiration System is designed to help address the challenges related to peripheral thrombectomies. Blood clots are said to be the third leading type of vascular disease.

It features a dual-lumen design to create the patented Surge Aspiration technology, a novel cyclic aspiration type at the distal end of the catheter.

Expanse ICE vascular device field serial entrepreneur Dr Eitan Konstantino said: “We’ve engineered the ICE catheter system to harness the aspiration power typical of a large bore catheter, but within the slender profile of a much smaller device.”

See Also:

Vascular Center Clinic in Arnsberg, Germany, angiology chief medical officer Dr Michael Lichtenberg said: “It is clear this device was built with physicians in mind. It aims to address some of the biggest issues we see regularly.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“The device was designed and built with a strong understanding of foundational physics that leaves me optimistic for its success.”

According to the US Centers for Disease Control, approximately one million patients face peripheral blood clots that must be treated annually, and up to 33% of them suffer complications in the long term.

Cleveland Clinic peripheral vascular interventions director Dr Aravinda Nanjundappa said: “I am looking forward to being among the first users of the Expanse ICE system. Its ability to offer powerful clot removal in a compact size is an intriguing proposition that could significantly enhance our ability to meet patient needs more effectively and improve treatment outcomes in peripheral vascular disease.”